Spero Therapeutics (SPRO) Return on Capital Employed (2017 - 2026)
Spero Therapeutics posted quarterly Return on Capital Employed of 23.1% for Q1 2026, up 14281.0% year-on-year from N/an in Q1 2025, and up 92.69% on a QoQ basis from 11.99% in Q4 2025.
Spero Therapeutics (SPRO) has 10 years of Return on Capital Employed data on file, last reported at 23.1% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 14281.0% year-over-year to 23.1%; the trailing twelve-month figure through Mar 2026 stood at 23.1% (up 14281.0% YoY), and the FY2025 full-year result was 7.81%, up 8313.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 23.1%, up from 11.99% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 23.61% in Q4 2023 and bottomed at 199.6% in Q3 2022.
- The 5-year median for Return on Capital Employed is 26.35% (2023), against an average of 51.63%.
- The widest annual swing landed in 2023, when Return on Capital Employed soared 19666 bps; it then slumped 13896 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 56.43% in 2022, then soared by 142 bps to 23.61% in 2023, then plunged by 542 bps to 104.41% in 2024, then surged by 111 bps to 11.99% in 2025, then jumped by 93 bps to 23.1% in 2026.
- The last three Return on Capital Employed figures came in at 23.1% (Q1 2026), 11.99% (Q4 2025), and 113.46% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | 23.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.10% |
| Dec 31, 2025 | 11.99% |
| Sep 30, 2025 | -113.46% |
| Jun 30, 2025 | -111.26% |
| Mar 31, 2025 | -119.71% |
| Dec 31, 2024 | -104.41% |
| Sep 30, 2024 | 3.02% |
| Jun 30, 2024 | 17.21% |
| Mar 31, 2024 | 19.25% |
| Dec 31, 2023 | 23.61% |
| Sep 30, 2023 | -2.94% |
| Jun 30, 2023 | -13.60% |
| Mar 31, 2023 | -26.35% |
| Dec 31, 2022 | -56.43% |
| Sep 30, 2022 | -199.60% |
| Jun 30, 2022 | -117.47% |
| Mar 31, 2022 | -110.67% |
| Dec 31, 2021 | -63.19% |
| Sep 30, 2021 | -69.00% |
| Jun 30, 2021 | -63.83% |
| Mar 31, 2021 | -57.92% |
| Dec 31, 2020 | -56.15% |
| Sep 30, 2020 | -78.56% |
| Jun 30, 2020 | -100.54% |
| Mar 31, 2020 | -94.23% |
| Dec 31, 2019 | -76.49% |
| Sep 30, 2019 | -47.26% |
| Jun 30, 2019 | -35.87% |
| Mar 31, 2019 | -31.35% |
| Dec 31, 2018 | -35.60% |
| Sep 30, 2018 | -48.60% |
| Jun 30, 2018 | -63.73% |
| Mar 31, 2018 | -55.19% |
| Dec 31, 2017 | -76.77% |